X4 Pharmaceuticals Files 8-K Report
Ticker: XFOR · Form: 8-K · Filed: Jul 19, 2024 · CIK: 1501697
| Field | Detail |
|---|---|
| Company | X4 Pharmaceuticals, Inc (XFOR) |
| Form Type | 8-K |
| Filed Date | Jul 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, biotech
TL;DR
X4 Pharma filed an 8-K on 7/19/24, standard corporate update.
AI Summary
On July 19, 2024, X4 Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company is based in Boston, Massachusetts, and operates in the biological products sector. It was formerly known as Arsanis, Inc. until September 20, 2010.
Why It Matters
This 8-K filing serves as a notification of significant events or changes for X4 Pharmaceuticals, Inc., which could impact investors and stakeholders.
Risk Assessment
Risk Level: low — This filing is a routine 8-K, indicating standard corporate reporting rather than a specific event with immediate high risk.
Key Numbers
- 001-38295 — Commission File Number (Identifies the company's SEC filing history)
- 27-3181608 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- X4 Pharmaceuticals, Inc. (company) — Registrant
- Arsanis, Inc. (company) — Former company name
- July 19, 2024 (date) — Date of report
- Boston, Massachusetts (location) — Principal executive offices
- 02134 (zip_code) — Business address zip code
FAQ
What is the primary purpose of this 8-K filing for X4 Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report current information as required by the Securities Exchange Act of 1934, specifically for events occurring on or before July 19, 2024.
When was X4 Pharmaceuticals, Inc. formerly known as Arsanis, Inc.?
X4 Pharmaceuticals, Inc. was formerly known as Arsanis, Inc. until September 20, 2010.
What is the principal executive office address for X4 Pharmaceuticals, Inc.?
The principal executive offices of X4 Pharmaceuticals, Inc. are located at 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134.
What is the Commission File Number for X4 Pharmaceuticals, Inc.?
The Commission File Number for X4 Pharmaceuticals, Inc. is 001-38295.
What is the IRS Employer Identification Number for X4 Pharmaceuticals, Inc.?
The IRS Employer Identification Number for X4 Pharmaceuticals, Inc. is 27-3181608.
Filing Stats: 465 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-07-19 08:17:51
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share XFOR The Nasdaq Stock Market
Filing Documents
- xfor-20240719.htm (8-K) — 26KB
- 0001628280-24-032266.txt ( ) — 152KB
- xfor-20240719.xsd (EX-101.SCH) — 2KB
- xfor-20240719_lab.xml (EX-101.LAB) — 23KB
- xfor-20240719_pre.xml (EX-101.PRE) — 13KB
- xfor-20240719_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On July 19, 2024, X4 Pharmaceuticals, Inc. (the "Company") posted an updated corporate presentation on the Company's website. To access the presentation, investors should visit the "Investors" section of the Company's website at www.x4pharma.com. The information furnished under this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. X4 PHARMACEUTICALS, INC. Date: July 19, 2024 By: /s/ Adam Mostafa Adam Mostafa Chief Financial Officer